Form 4: Tenax Therapeutics Director Buys Shares
Insider Transaction (Form 4)
Declan Doogan, a Director of Tenax Therapeutics, Inc., purchased 53,000 shares of common stock on September 16, 2026 for $1.92 per share.
Summary
- Open-market purchase: acquired 53,000 Common Stock at $1.92 ($101,760) on September 16, 2026; holds 55,274 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $101,760, committing personal capital to the stock.
Insider Transactions
Declan Doogan — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Open-market purchase | Common Stock | 53,000 | $2 | $101.8K | 55,274 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Open-market purchase (53,000 shares) |
Keywords
insider transaction, Form 4, TENX, TENAX THERAPEUTICS, INC., bullish, Declan Doogan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.